Assessing Azenta (AZTA) Valuation After Recent Share Price Rebound And Margin Expansion Hopes

Recent share performance and business snapshot

Azenta (AZTA) has drawn attention after a recent 1 day share move of 6.8%, capping a week where the stock returned 13.7%, despite negative returns over the month and past 3 months.

The company, valued at about US$1.0b with a last close of US$22.63, focuses on biological and chemical sample management and multiomics services across the United States, Europe, Asia Pacific, and China.

See our latest analysis for Azenta.

The recent 1 day share price return of 6.85% and 7 day gain of 13.72% come after a weaker patch, with the 30 day share price return of 6.87% and year to date share price return of 32.23% contributing to a 1 year total shareholder return of 22.29%. This indicates that momentum has picked up in the short term after a tougher longer run.

If this kind of rebound has your attention, it could be a good moment to see what else is moving and uncover 36 healthcare AI stocks

With Azenta trading at a discount to both some analyst targets and an intrinsic estimate, yet showing weak multi-year returns, readers may wonder whether this represents a reset that opens a potential buying opportunity or whether markets already incorporate expectations for future growth in the current price.

Most Popular Narrative: 41.5% Undervalued

Azenta's most followed narrative places fair value at $38.67 per share versus the last close of $22.63, highlighting a wide gap that depends on future earnings power and margin resilience.

The ongoing trend of life sciences digitization and automation is reflected in Azenta's improved operational execution and introduction of more automated solutions; these efficiency gains, alongside investments in R&D and product management, are producing significant gross margin and EBITDA margin expansion, pointing to further net margin improvements with scale.

Read the complete narrative.

Want to see what sits behind that confidence in margins and earnings? The narrative focuses on steady revenue growth, rising profitability, and a rich future earnings multiple that has to be earned over time.

Result: Fair Value of $38.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh risks, such as delayed orders in higher margin tools and ongoing pressure in gene synthesis and Sanger sequencing services.

Find out about the key risks to this Azenta narrative.

Another angle on valuation

The narrative and analyst targets suggest Azenta is undervalued at $22.63 versus fair value estimates around $38 to $43. However, its current P/E of 39.6x is higher than both the North American Life Sciences average of 37.4x and a fair ratio of 18.5x, which points to clear valuation risk if earnings or sentiment slip.

The gap between the current P/E, peers, and the fair ratio raises a simple question for you: Is the discount to fair value a cushion, or a sign that expectations still need to cool further before the balance of risk and reward feels comfortable?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

All of this leaves a mixed picture, with clear reasons for both caution and optimism, so it makes sense to review the data yourself and move quickly while sentiment is still forming. To help round out that view, take a closer look at the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Azenta caught your eye, do not stop here. Use the screener to quickly surface fresh opportunities that match what you care about in a portfolio.

• Target resilient returns by focusing on companies with strong balance sheets and healthy fundamentals through the solid balance sheet and fundamentals stocks screener (40 results).
• Hunt for quality at sensible prices by scanning a curated set of potential value opportunities using the 58 high quality undervalued stocks.
• Strengthen your income stream by zeroing in on companies that offer higher yields with the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com